Olivia Lutz

Olivia Lutz

Auto-generated profile, based on publicly available information

Olivia Lutz

Beth Israel Deaconess Medical Center, Boston, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PLPaulo Lizano
Paulo Lizano
OLOlivia Lutz
Olivia Lutz
GLGeorge Ling
George Ling
ALAdam M. Lee
Adam M. Lee
SESeenae Eum
Seenae Eum
MKMatcheri Keshavan
Matcheri Keshavan

15 October 2020 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
PLPaulo Lizano
Paulo Lizano
OLOlivia Lutz
Olivia Lutz
YXYanxun Xu
Yanxun Xu
LRLeah H. Rubin
Leah H. Rubin
LPLyle Paskowitz
Lyle Paskowitz
JBJeffrey R Bishop
Jeffrey R Bishop

17 September 2019 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
NANey Alliey-Rodriguez
Ney Alliey-Rodriguez
TGTamar A. Grey
Tamar A. Grey
RSRebecca Shafee
Rebecca Shafee
HAHuma Asif
Huma Asif
OLOlivia Lutz
Olivia Lutz
EGElliot S. Gershon
Elliot S. Gershon
Schizophrenia, Schizoaffective, and Bipolar disorders share behavioral and phenomenological traits, intermediate phenotypes, and some associated genetic loci with pleiotropic effects. Volumetric abnormalities in brain structures are among the intermediate phenotypes consistently reported associated with these disorders. In order to examine the genetic underpinnings of these structural brain modifications, we performed genome-wide association analyses (GWAS) on 60 quantitative structural brain MRI phenotypes in a sample of 777 subjects (483 cases and 294 controls pooled together). Genotyping was performed with the Illumina PsychChip microarray, followed by imputation to the 1000 genomes multiethnic reference panel. Enlargement of the Temporal Horns of Lateral Ventricles (THLV) is associated with an intronic SNP of the gene NRXN1 (rs12467877,P = 6.76E–10), which accounts for 4.5% of the variance in size. Enlarged THLV is associated with psychosis in this sample, and with reduction of the hippocampus and enlargement of the choroid plexus and caudate. Eight other suggestively significant associations (P < 5.5E–8) were identified with THLV and 5 other brain structures. Although rare deletions of NRXN1 have been previously associated with psychosis, this is the first report of a common SNP variant of NRXN1 associated with enlargement of the THLV in psychosis.

1 April 2019 in NeuroImage
Verified
Journal Article
Closed access
GLGeorge Ling
George Ling
ILIvy Lee
Ivy Lee
SGSynthia Guimond
Synthia Guimond
OLOlivia Lutz
Olivia Lutz
NTNeeraj Tandon
Neeraj Tandon
RBRoscoe Brady
Roscoe Brady

1 June 2018 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
SGSynthia Guimond
Synthia Guimond
SPShezal Padani
Shezal Padani
OLOlivia Lutz
Olivia Lutz
SEShaun Eack
Shaun Eack
HTHeidi Thermenos
Heidi Thermenos
MKMatcheri Keshavan
Matcheri Keshavan

11 October 2018 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
PLPaulo Lizano
Paulo Lizano
OLOlivia Lutz
Olivia Lutz
GLGeorge Ling
George Ling
JPJaya Padmanabhan
Jaya Padmanabhan
NTNeeraj Tandon
Neeraj Tandon
MKMatcheri Keshavan
Matcheri Keshavan
Vascular endothelial growth factor A (VEGFA) dysfunction may contribute to a number of pathological processes that characterize psychotic disorders. However, the influence of VEGFA gene variants on clinical and neuroimaging phenotypes in psychotic disorders has yet to be shown. In the present study, we examined whether different VEGFA gene variants influence psychosis risk, symptom severity, cognition, and brain volume. The study group included 480 probands (Bipolar I disorder with psychosis, n = 205; Schizoaffective disorder, n = 112; Schizophrenia, n = 163) and 126 healthy controls that were recruited across six sites in the B-SNIP consortium. VEGFA variants identified for analysis (rs699947, rs833070, and rs2146323) were quantified via SNP chip array. We assessed symptoms and cognition using standardized clinical and neuropsychological batteries. The dorsolateral prefrontal cortex (DLPFC), medial temporal lobe, and hippocampal volumes were quantified using FreeSurfer. In our sample, VEGFA rs2146323 A- carriers showed reduced odds of being a proband (p = 0.037, OR = 0.65, 95% CI = 0.43–0.98) compared to noncarriers, but not for rs699947 or rs833070. In probands, rs2146323 A- carriers demonstrated fewer hallucinations (p = 0.035, Cohen’s d = 0.194), as well as significantly greater DLPFC (p < 0.05, Cohen’s d = −0.21) and parahippocampal volumes (p < 0.01, Cohen’s d = −0.27). No clinical or neuroimaging associations were identified for rs699947 or rs833070. In general, we found that the three SNPs exhibited several significant negative relationships between psychosis symptoms and brain structure. In the probands and control groups, positive relationships were identified between several cognitive and brain volume measures. The findings suggest VEGFA effects in the DLPFC and hippocampus found in animals may also extend to humans. VEGFA variations may have important implications in identifying dimensional moderators of function that could be targeted through VEGFA-mediated interventions.